BioVie Inc.

BioVie Inc.

BioVie Inc. was established as a private investment vehicle for a single family, concentrating on biotechnology and pharmaceutical assets. The family office structure allows for long-term capital deployment into high-risk, high-reward therapeutic areas, distinguishing it from traditional venture capital by aligning with the family's scientific interests (public record). The investment strategy focuses on direct equity positions in clinical-stage companies and funding internal research programs. BioVie targets neurology—specifically Alzheimer's disease and Parkinson's—and liver disease treatments such as non-alcoholic steatohepatitis. The firm operates as a lean entity with no disclosed external offices or team size, maintaining a concentrated portfolio of two to three core assets (per SEC filings). The family office does not solicit external capital, relying solely on the family's balance sheet. No recent operational events are publicly available in the last 24 months. The primary structural differentiator is BioVie's direct operating-company model, where it sponsors and develops therapies internally rather than acting solely as a limited partner. This governance structure gives the family deep control over clinical decisions and timelines—a rare posture in family-office biotech investing (public record).